Insight Molecular Diagnostics Inc. IMDX

NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” Conference taking place September 10th, 2026 in New York. Event: Lake Street Capital Markets 10th Annual Best Ideas Growth “BIG10” ConferenceWho: Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea JamesDate: Thursday, September 10, 2026Location: Metropolit

NASHVILLE, Tenn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will host a virtual key opinion leader (KOL) event on Monday, August 17, 2026 at 11AM ET featuring Max Jacob Liebo, MD (Loyola University Medical Center), who will join Nick Ioannou, MD, MHA (iMDx VP Medical Affairs) and Josh Riggs (iMDx CEO), to discuss the Company's GraftAssure platform, which leverages digital PCR technology to deliver reliable dd-cfDNA resul

Moby summary of Insight Molecular Diagnostics Inc.'s Q2 2026 earnings call

Discussions with FDA advance toward expected marketing authorization for GraftAssureDxFDA completes current portion of substantive review in a timely mannerFavorable Medicare reimbursement policy issued in July significantly increases GraftAssureDx surveillance testing opportunityStrong head-to-head data drive kitted customer interest NASHVILLE, Tenn., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders

NASHVILLE, Tenn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report second quarter 2026 financial results after the market closes on Monday, August 10, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDx Q2 2026 Earnin

Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejectionSerial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisionsNew study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trialsiMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring wit

Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testingSupports iMDx's commercial strategy in transplant monitoringFinal policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratoriesFinal policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagn

Key member of management ranks at top 2% of researchers in the field of laboratory diagnostics and top 2.5% of all researchers worldwide, based on H-index of 58Recent studies advanced science of molecular diagnostic testing for transplanted organ rejection, published in Clinical Chemistry, Transplant International, American Journal of Transplantation and Nephrology Dialysis Transplantation, among others NASHVILLE, Tenn., June 29, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasd

-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation- NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), and the American Society of Transplant Surgeons (ASTS) today announced the selection of Kenneth Andreoni, MD, Surgical Director of Kidney Transplantation at Thomas Jefferson University, and Kenneth Chavin, MD, MBA, PhD, FACS, of Temple Health, as the recipients of the

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is one of the high-growth micro-cap stocks to buy now. On June 11, Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) announced the online publication in the American Journal of Transplantation of new data demonstrating the statistical superiority of its flagship GraftAssure transplant rejection monitoring assay. The study showed that the novel GraftAssure […]

Peer-reviewed journal Clinical Chemistry published the first head-to-head study comparing GraftAssure™ to industry-leading competitorGraftAssure’s industry-leading reference change value (time-point to time-point change) supports transplanted organ health screening and rejection recurrence monitoring NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, t

American Journal of Transplantation publishes public pre-proof showing novel CM-score superior to either fractional or absolute measurement of dd-cfDNA aloneGraftAssure™ assay doubles reliability of positive results in screening cohortIn for-cause testing of kidney transplant patients, the positive predictive value using the CM-Score increased to greater than 80% NASHVILLE, Tenn., June 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced an onl

Multiple events and presentations will highlight potential benefits of in-house transplanted-organ-rejection testing, and of GraftAssure technology specificallyMajor transplantation conference in Boston will create additional awareness about GraftAssure technology and its differentiation and potential applicationsiMDx to also announce sponsorship of a grant for researchers to evaluate economics of in-house, transplanted-organ-rejection testing NASHVILLE, Tenn., June 09, 2026 (GLOBE NEWSWIRE) --

Insight Molecular Diagnostics now sits under a refreshed analyst narrative, with a price target that has moved to US$12 per share alongside an updated fair value estimate of US$10.50. Analysts linking this change to the recent US$26m offering and the pending GraftAssureDx FDA submission frame the new target as closely tied to funding progress and upcoming regulatory milestones. As you read on, you will see how these shifting assumptions and catalysts are shaping the story and how you can keep...

Moby summary of Insight Molecular Diagnostics Inc.'s Q1 2026 earnings call

Insight Molecular Diagnostics Inc (IMDX) showcases international expansion and regulatory progress, while navigating financial hurdles and market uncertainties.